olivLaw · US equity research
The Cigna Group CI
Hospital & Medical Service Plans · SIC 6324 · Vertical: Hospital & Medical Service Plans (SIC 6324)
The Cigna Group (CI) is a global health company operating through two segments, Evernorth Health Services and Cigna Healthcare. In the second quarter of 2026 total revenues were 71.7 billion USD, and the 2026 outlook for adjusted income from operations was raised to at least 30.45 USD per share. The company describes intense price competition and ongoing margin pressure, which could affect future results.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, The Cigna Group (CI) stock was 305.41 USD (+3.37% on the day), with market capitalisation 80.7 bn USD, P/E 13.2 on diluted EPS of 23.08 USD over the last 12 months, dividend yield 2.01%, beta 0.11, 52-week range 256.38–315.88 USD. Latest reported quarter (Q2 2026): revenue of 71.7 bn USD (+6.7% YoY), net income of 1.7 bn USD (+8.4% YoY), diluted EPS 6.29 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 60.8
- strong (55–70)
- Bollinger (20, 2)
- 278.68 – 315.73
- in the upper half of the band · %B 0.72 · band width 12.5%
- SMA 50 / 200
- 285.08 / 282.02
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 4.87 / 5.56
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +12.6% | −1.1% | +13.7 pp | — |
| 3 months | +12.9% | −0.5% | +13.4 pp | — |
| 6 months | +8.3% | +4.4% | +3.9 pp | — |
| Year to date | +11.0% | +12.3% | −1.4 pp | — |
| 1 year | +15.4% | +13.5% | +1.9 pp | +52.7% |
| 3 years | −1.7% | +76.4% | −78.1 pp | +3.2% |
| 5 years | +42.6% | +63.7% | −21.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 63.7 bn | 65.6 bn | 65.5 bn | 67.2 bn | 69.7 bn | 72.5 bn | 68.5 bn | 71.7 bn |
| Cost of revenue | 47.6 bn | 49.0 bn | 48.4 bn | 53.3 bn | 55.5 bn | 57.8 bn | 54.1 bn | 56.7 bn |
| SG&A | 3.6 bn | 3.9 bn | 4.2 bn | 3.4 bn | 3.4 bn | 3.6 bn | 3.7 bn | 3.5 bn |
| Operating income | 2.6 bn | 2.2 bn | 2.0 bn | 2.3 bn | 2.6 bn | 2.3 bn | 2.4 bn | 2.7 bn |
| Depreciation & amortisation | 650.0 m | 646.0 m | 674.0 m | 682.0 m | 697.0 m | 722.0 m | 650.0 m | 655.0 m |
| Interest expense | 380.0 m | 400.0 m | 362.0 m | 338.0 m | 363.0 m | 300.0 m | 357.0 m | 359.0 m |
| Pre-tax income | 1.2 bn | 2.0 bn | 1.6 bn | 2.0 bn | 2.3 bn | 1.8 bn | 2.3 bn | 2.3 bn |
| Income tax | 367.0 m | 473.0 m | 239.0 m | 389.0 m | 322.0 m | 543.0 m | 409.0 m | 382.0 m |
| Net income | 825.0 m | 1.2 bn | 1.3 bn | 1.5 bn | 2.0 bn | 943.0 m | 1.7 bn | 1.7 bn |
| Diluted EPS | 2.63 | 4.29 ≈ | 4.85 | 5.71 | 6.98 | 3.55 ≈ | 6.26 | 6.29 |
| Operating cash flow | 46.0 m ≈ | 5.2 bn | 1.9 bn | -1.9 bn ≈ | 3.4 bn ≈ | 6.1 bn | 1.1 bn | -421.0 m ≈ |
| Dividends paid | 390.0 m ≈ | 384.0 m | 412.0 m | 401.0 m ≈ | 402.0 m ≈ | 396.0 m | 417.0 m | 409.0 m ≈ |
| Share repurchases | 0 ≈ | 2.0 bn | 1.5 bn | 1.1 bn ≈ | 0 ≈ | 1.0 bn | 0 | 280.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 34 percentile of its own 35-quarter history (min 8.4, median 14.8, max 34.1; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48.7 bn | 153.6 bn | 160.4 bn | 174.1 bn | 180.5 bn | 195.3 bn | 247.1 bn | 274.9 bn |
| Revenue YoY | +16.4% | +215.7% | +4.5% | +8.5% | +3.7% | +8.2% | +26.6% | +11.2% |
| Net income | 2.6 bn | 5.1 bn | 8.5 bn | 5.4 bn | 6.8 bn | 5.2 bn | 3.4 bn | 6.0 bn |
| Net income YoY | +18.5% | +93.5% | +65.8% | −36.2% | +25.1% | −23.9% | −33.5% | +73.5% |
| Diluted EPS | 10.54 | 13.44 | 22.96 | 15.75 | 21.41 | 17.39 | 12.12 | 22.18 |
| Diluted EPS YoY | +20.2% | +27.5% | +70.8% | −31.4% | +35.9% | −18.8% | −30.3% | +83.0% |
| net % | 5.4% | 3.3% | 5.3% | 3.1% | 3.8% | 2.6% | 1.4% | 2.2% |
| Free cash flow | 3.2 bn | 8.4 bn | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 7.7 bn USD
- Financial debt
- 592.0 m USD
- Net debt
- -7.1 bn USD
- Equity
- 41.9 bn USD
- Total assets
- 157.9 bn USD
- Debt / equity
- 0.01x
- Current ratio
- 0.85x
- ROE
- 14.3%
- ROA
- 3.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Pre-tax income | 10.9 bn | 6.8 bn | 8.4 bn | 5.5 bn | 5.3 bn | 7.8 bn | SEC (XBRL)· 26 Feb 2026verified |
| Net income | 8.5 bn | 5.4 bn | 6.8 bn | 5.2 bn | 3.4 bn | 6.0 bn | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | 22.96 | 15.75 | 21.41 | 17.39 | 12.12 | 22.18 | SEC (XBRL)· 26 Feb 2026verified |
| Dividend per share | 0.04 | 4.00 | 4.48 | 4.92 | 5.60 | 6.04 | SEC (XBRL)· 26 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 10.2 bn | 5.1 bn | 5.9 bn | 7.8 bn | 7.6 bn | 7.7 bn | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 155.5 bn | 154.9 bn | 143.9 bn | 152.8 bn | 155.9 bn | 157.9 bn | SEC (XBRL)· 26 Feb 2026verified |
| Short-term debt | 3.4 bn | 2.5 bn | 3.0 bn | 2.8 bn | 3.0 bn | 592.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 105.1 bn | 107.7 bn | 99.1 bn | 106.4 bn | 114.6 bn | 116.0 bn | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 50.2 bn | 47.0 bn | 44.7 bn | 46.2 bn | 41.2 bn | 41.9 bn | SEC (XBRL)· 26 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Dividends paid | 15.0 m | 1.3 bn | 1.4 bn | 1.5 bn | 1.6 bn | 1.6 bn | SEC (XBRL)· 26 Feb 2026verified |
| Share repurchases | 4.0 bn | 7.7 bn | 7.6 bn | 2.3 bn | 7.0 bn | 3.6 bn | SEC (XBRL)· 26 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Market and valuation
Insurance
32 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 73 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 80.7 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation93
- Returns48
- Quality75
- Balance sheet100
- Growth51
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 79.37 – 1,336.67 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- Residual income178.68 – 186.89 (Mid 182.71)
- Justified P/B259.35 – 348.78 (Mid 297.49)
- Dividend discount (DDM)79.37 – 106.74 (Mid 91.04)
- Peers: P/E561.01 – 1,336.67 (Mid 600.74)7 companies used · median multiple 26.0x · quartiles 24.3x – 57.9xALHC, CNC, ELV, HUM, OSCR, TRUP, UNH
- Peers: P/B362.74 – 540.84 (Mid 446.93)6 companies used · median multiple 2.8x · quartiles 2.2x – 3.4xCNC, ELV, HUM, MOH, TRUP, UNH
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 73/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROE · Quality | 15.0% | 75 (vs peers) | 20% |
| Loss ratio · Quality | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | 1.2% | 12 (on a fixed band) | 11% |
| Revenue CAGR 3Y · Growth | 15.0% | 100 (on a fixed band) | 9% |
| ROA · Balance sheet | 4.0% | 100 (on a fixed band) | 9% |
| P/B · Valuation | 1.9x | 86 (vs peers) | 16% |
| P/E (TTM) · Valuation | 13.2x | 100 (vs peers) | 16% |
| Dividend yield · Returns | 2.0% | 17 (on a fixed band) | 11% |
| Payout ratio (EPS) · Returns | 26.6% | 100 (on a fixed band) | 7% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 1/1 factors with a value
- Growth51/100 · 2/2 factors with a value
- Quality· partial75/100 · 1/2 factors with a value
- Returns48/100 · 2/2 factors with a value
- Valuation93/100 · 2/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
The Cigna Group (CI). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: YoY growth 11.2%; net margin 2.2%; ROE 15.0%.
The estimated value range is 259.35–348.78 USD per share (median of 5 methods, agreement: low); assumptions are illustrative. Against the central value of 297.49 USD, the price of 305.41 USD leaves a potential of -2.6% (value / price − 1) and a margin of safety of -2.7% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 73/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: quality. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROE: 15.0%
- Revenue CAGR 3Y: 15.0%
- ROA: 4.0%
- P/B: 1.9x
- P/E (TTM): 13.2x
- Payout ratio (EPS): 26.6%
What contradicts it
- EPS CAGR 3Y: 1.2%
- Dividend yield: 2.0%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Loss ratio.
Versus the vertical median
Hospital & Medical Service Plans (SIC 6324) · same industry (4-digit SIC) · compared with 9 companies
The size band was not applied: too few companies would have remained; the vertical includes much smaller or larger companies.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| UNHUnitedHealth Group Incorporated | 366.8 bn | 23.4 | 15.4% | 3.5% | +11.8% | +24% / −26% |
| ELVElevance Health, Inc. | 93.8 bn | 18.5 | 11.6% | 2.5% | +12.5% | +28% / −9% |
| CIThe Cigna Group | 80.7 bn | 13.2 | 15.0% | 2.2% | +11.2% | +15% / −2% |
| HUMHumana Inc | 50.1 bn | 44.5 | 6.2% | 0.8% | +10.1% | +70% / −14% |
| CNCCentene Corporation | 37.6 bn | 26.0 | 6.8% | 0.7% | +19.4% | +93% / +3% |
| MOHMolina Healthcare, Inc. | 11.8 bn | — | -1.2% | -0.1% | +11.7% | +53% / −38% |
| ALHCAlignment Healthcare, Inc. | 1.7 bn | 71.3 | 13.2% | 0.6% | +46.1% | −58% / +9% |
| TRUPTrupanion, Inc. | 1.5 bn | 74.8 | — | — | +11.9% | −5% / +31% |
| OSCROscar Health, Inc. | — | 25.2 | 34.3% | 3.6% | +27.5% | +96% / +314% |
| CLOVClover Health Investments, Corp. | — | — | -5.1% | -0.7% | +40.3% | +88% / +409% |
1- and 3-year price returns: for CI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 203.88 Total return -31% · Per year -31% | 358.80 Total return 20% · Per year 20% | 538.20 Total return 79% · Per year 79% |
| 3 years | 241.83 Total return -15% · Per year -5% | 474.51 Total return 64% · Per year 18% | 775.01 Total return 164% · Per year 38% |
| 5 years | 286.85 Total return 5% · Per year 1% | 627.54 Total return 121% · Per year 17% | 1,116.01 Total return 287% · Per year 31% |
- Exit P/E± 118.63
- Net margin± 83.04
- Annual revenue growth± 61.93
- Annual dilution± 6.98
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Jul 2026; since then the company filed 8-K (05 Nov 2026 · results).
In brief
The Cigna Group (CI) is a global health company operating through two segments, Evernorth Health Services and Cigna Healthcare 1. In the second quarter of 2026 total revenues were 71.7 billion USD, and the 2026 outlook for adjusted income from operations was raised to at least 30.45 USD per share 3. The company describes intense price competition and ongoing margin pressure, which could affect future results 1.
SWOT
Strengths
- The company has a broad client base and a network of partnerships with pharmacies and health providers, giving it operating scale 1.
- Combining pharmacy and medical capabilities allows integrated solutions for clients and patients 1.
- Growth in Specialty and Care Services and operating efficiency reported for 2026 point to solid execution capacity 3.
Weaknesses
- Margins in the pharmacy segment are pressured by competition and client demands for lower prices 1.
- Reliance on a few large clients and large pharmacy chains creates exposure to renegotiation risk 1.
- Pharmacy Benefit Services profit declined in the second quarter of 2026, indicating pressure on that business 3.
Opportunities
- The rebate-free model could attract clients seeking more transparent pharmacy costs 1.
- Greater adoption of generic and biosimilar drugs could support both client savings and specialty service profitability 3.
- Redirecting resources after exiting the Individual and Family Plans business could focus the company on higher-growth areas 2.
Risks
- Difficult-to-predict medical costshigh
Small differences between estimated and actual medical costs can produce large swings in financial results, especially if costly treatments or external events arise 1.
- Competitive pressure on pricinghigh
Clients can easily compare competing offers and may seek lower prices or performance guarantees, which could compress margins 1.
- Dependence on pharmacy relationshipsmedium
Pharmacy contracts are generally nonexclusive and terminable on short notice, and losing a major chain could affect client access 1.
- Relationship with drug manufacturersmedium
Manufacturer contracts are typically nonexclusive and can be terminated quickly, and changes to rebate practices could alter collaboration terms 1.
- Regulation of drug prices and rebatesmedium
Legislation and executive actions on drug prices and rebates could limit the company's ability to set its pricing 1.
Investment thesis
What would need to be true (bull case)
What would break the thesis
What to watch
- Quarterly results and the adjusted per-share outlook for 2026Q3 2026
- Effects of exiting the Individual and Family Plans business on Cigna Healthcare2027
- Rollout of the rebate-free model in the pharmacy segment2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 30 Jul 2026; since then the company filed 8-K (05 Nov 2026 · results).
The business
The Cigna Group, through its subsidiaries, describes its mission as improving the health and vitality of those it serves, with approximately 67,700 colleagues at the end of 2025 and more than 185 million customer relationships in more than 30 markets and jurisdictions 1. The company has two segments, Evernorth Health Services, which includes Pharmacy Benefit Services and Specialty and Care Services, and Cigna Healthcare, which includes U.S. Healthcare and International Health 1. According to the annual report description, the two segments combine pharmacy and medical capabilities to improve affordability, transparency and health outcomes 1.
In fiscal 2025, total revenues were 274.9 billion USD, and notable developments included the sale of the Medicare Advantage businesses to Health Care Service Corporation, completed on March 19, 2025, with total cash proceeds of 4.9 billion USD 1. The company also launched a strategic optimization program, with costs of 749 million USD pre-tax in 2025 and expected annualized after-tax savings of at least 500 million USD 1.
According to the second quarter 2026 quarterly report, total customer relationships fell to 182.8 million at June 30, 2026, mainly due to expected client transitions in the pharmacy business, while medical customers rose slightly 3. In April 2026 the company announced it would exit the Individual and Family Plans medical business as of January 1, 2027 2.
Segments
Evernorth Health Services
The Evernorth Health Services segment generated adjusted revenues of 235 billion USD in fiscal 2025 and pre-tax adjusted income from operations of 7.2 billion USD, with the largest contributions coming from Pharmacy Benefit Services and Specialty and Care Services 1. In the second quarter of 2026 segment adjusted revenues rose 6% while pre-tax adjusted income fell 2%, reflecting client-focused and customer-focused initiatives 3.
Corporate and other operations
Corporate includes interest, amounts not allocated to operating segments and intersegment eliminations, while Other Operations covers the COLI business, run-off operations and other non-strategic businesses 1. These units are smaller, but unallocated costs can still influence consolidated profit 2.
Market context
The company operates in a competitive market that includes independent and managed care pharmacy benefit managers, home delivery and specialty pharmacies, specialty drug distributors, health plans and care services providers 1. The source describes the industry as rapidly changing with price pressure, and in pharmacy one large chain group represents about 47% of stores in the largest network 1.
More than 65,000 pharmacies participated in at least one of the company's networks as of December 31, 2025, indicating broad reach but also dependence on large chain relationships 1. If a major chain ended its relationship or renegotiated less favorable terms, client access to pharmacies and claims volume could be affected 1.
Trends
- Pricing pressure in pharmacyheadwind
Strong competition in the pharmacy benefit business has increased demand for lower prices and greater sharing of rebates, pressuring margins 1. The company has announced a rebate-free model that could support client retention, though it could also change negotiating dynamics with manufacturers 1.
- Operating efficiency and cost reductiontailwind
The strategic optimization program and lower SG&A spending could support margins if the announced savings materialize 1. In the second quarter of 2026 the SG&A expense ratio declined, reflecting operating efficiency 3.
- Premium increases in the medical segmentmixed
Cigna Healthcare revenue growth in 2026 reflects premium rate increases intended to cover higher expected medical costs, though this depends on cost trends and client contracts 3. Exiting the Individual and Family Plans business in 2027 could change the segment revenue mix 2.
- Regulation and drug pricingheadwind
Laws such as the Inflation Reduction Act allow the government to negotiate certain drug prices, and legislative proposals and executive actions can shift pharmacy economics 1. These changes could affect margins and competitive position if not anticipated 1.
Competitive position
Primary competitive factors include the ability to negotiate with pharmacies and drug manufacturers, manage specialty drug costs and deliver integrated health services 1. The company believes its focus on the health and vitality of those it serves can differentiate it from primary competitors 1.
Competition includes both independent pharmacy benefit managers and managed care organizations, but the source does not provide comparable market shares for each competitor 1. If competitors have greater resources or capabilities, the company could lose clients or be pushed to reduce prices 1.
- Independent pharmacy benefit managers
Pharmacy-segment competitors named in the source without a specific company name.
- Managed care and health insurance providers
Medical-segment competitors, including health plans, referred to generically in the annual report.
- Home delivery and specialty pharmacies
Competitors offering similar pharmacy services, without specific names in the source.
- Specialty drug distributors and care services providers
Competitors in complex drug distribution and care services, listed generically in the sources.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Cigna Profit Tops Wall Street Views on Insurance, Care ServicesBloomberg Markets · 05 Nov 2026 · EN
- Cigna Group Executive Neville Everett Sells 617 Shares for $175,000Yahoo Finance — News · 09 Sept 2026 · EN
- Cigna Healthcare on Business StrategyBloomberg Markets · 08 Sept 2026 · EN
- How Is The Cigna Group’s Stock Performance Compared to Other Healthcare PlansYahoo Finance — News · 02 Sept 2026 · EN
- XRP Treasury Firm Evernorth Clears SEC Hurdle as Public Market Debut NearsYahoo Finance — News · 28 Aug 2026 · EN
SEC filings
- Current report05 Nov 2026Results of operations · Financial statements and exhibits
- Current report09 Oct 2026Departure or appointment of officers
- Current report30 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report30 Jul 2026
- Current report30 Jul 2026Results of operations · Financial statements and exhibits
- Current report13 May 2026Regulation FD disclosure
- Quarterly report30 Apr 2026
- Current report30 Apr 2026Results of operations · Financial statements and exhibits
- Current report27 Apr 2026Shareholder vote
- Proxy statement13 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / The Cigna Group · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / The Cigna Group · 30 Jul 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / The Cigna Group · 30 Jul 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.